Howard G. Birnbaum

Howard G. Birnbaum

Auto-generated profile, based on publicly available information

Howard G. Birnbaum

Analysis Group, Inc., Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
HBHoward G. Birnbaum
Howard G. Birnbaum
AWAlan G. White
Alan G. White
MSMatt Schiller
Matt Schiller
TWTracy Waldman
Tracy Waldman
JCJody M. Cleveland
Jody M. Cleveland
CRCarl L. Roland
Carl L. Roland

30 June 2009 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
HBHoward G. Birnbaum
Howard G. Birnbaum
RKRonald C. Kessler
Ronald C. Kessler
DKDavid Kelley
David Kelley
RBRym Ben-Hamadi
Rym Ben-Hamadi
VJVijay N. Joish
Vijay N. Joish
PGPaul E. Greenberg
Paul E. Greenberg
Background: Treatment utilization/costs and work performance for persons with major depressive disorder (MDD) by severity of illness is not well documented. Methods: Using National Comorbidity Survey‐Replication (2001–2002) data, US workforce respondents (n=4,465) were classified by clinical severity (not clinically depressed, mild, moderate, severe) using a standard self‐rating scale [Quick Inventory of Depressive Symptomatology Self‐Report (QIDS‐SR)]. Outcomes included 12‐month prevalence of medical services/medications use/costs and workplace performance. Treatment costs (employer's perspective) were estimated by weighing utilization measures by unit costs obtained for similar services used by MDD patients in claims data. Descriptive analysis across three severity groups generated χ2 results. Results: Using a sample of 539 US workforce respondents with MDD, 13.8% were classified mild, 38.5% moderate, and 47.7% severe cases. Mental health services usage, including antidepressants, increased significantly with severity, with average treatment costs substantially higher for severe than for mild cases both regarding mental health services ($697 vs. $388, χ2=4.4, P=.019) and antidepressants ($256 vs. $88, χ2=9.0, P=.001). Prevalence rates of unemployment/disability increased significantly (χ2=11.7, P=.003) with MDD severity (15.7, 23.3, and 31.3% for mild, moderate, and severe cases). Severely and moderately depressed workers missed more work than nondepressed workers; the monthly salary‐equivalent lost performance of $199 (severely depressed) and $188 (moderately depressed) was significantly higher than for nondepressed workers (χ2=10.3, P<.001). Projected to the US workforce, monthly depression‐related worker productivity losses had human capital costs of nearly $2 billion. Conclusions: MDD severity is significantly associated with increased treatment usage/costs, treatment adequacy, unemployment, and disability and with reduced work performance. Depression and Anxiety, 2010.

12 November 2009 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
HBHoward Birnbaum
Howard Birnbaum
CPCrystal Pike
Crystal Pike
RKRebecca Kaufman
Rebecca Kaufman
MMMaryna Maynchenko
Maryna Maynchenko
YKYohanne Kidolezi
Yohanne Kidolezi
MCMary Cifaldi
Mary Cifaldi
(2010). Societal cost of rheumatoid arthritis patients in the US. Current Medical Research and Opinion: Vol. 26, No. 1, pp. 77-90. doi: 10.1185/03007990903422307

1 February 2005 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
HBHoward G. Birnbaum
Howard G. Birnbaum
RKRonald C. Kessler
Ronald C. Kessler
SLSarah W. Lowe
Sarah W. Lowe
KSKristina Secnik
Kristina Secnik
PGPaul E. Greenberg
Paul E. Greenberg
ASAndrine R. Swensen
Andrine R. Swensen
The objective of this study is to provide a comprehensive estimate of the cost of ADHD by consider ing the healthcare and work loss costs of persons with ADHD, as well as those costs imposed on their family members. Excess per capita healthcare (medical and prescription drug) and work loss (disability and work absence) costs of treated ADHD patients (ages 7 years-44 years) and their family members (under 65 years of age) were calculated using administrative claims data from a single large company; work loss costs are from disability data or imputed for medically related work loss days. Excess costs are the additional costs of patients and their family members over and above those of comparable control individuals. The excess costs of untreated individuals with ADHD and their family members were also estimated. All per capita costs were extrapolated using published prevalence and treatment rates and population data; the prevalence of persons with ADHD was based upon the literature. The total excess cost of ADHD in the US in 2000 was $31.6 billion. Of this total, $1.6 billion was for the ADHD treatment of patients, $12.1 billion was for all other healthcare costs of persons with ADHD, $14.2 billion was for all other healthcare costs of family members of persons with ADHD, and $3.7 billion was for the work loss cost of adults with ADHD and adult family members of persons with ADHD. The annual cost of ADHD in the US is substantial. Both treated and untreated persons with ADHD, as well as their family members, impose consider able economic burdens on the healthcare system as a result of this condition. While these first estimates of the cost of ADHD to the nation are suggestive of its substantial economic burden, future research needs to refine and build on this analysis, particularly in the context of a model to control for related co-morbidities. Similarly, since these results are based on data from a single company for the period 1996-1998, the analysis should be validated with more representative, current data.

1 December 2003 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
ASAndrine R. Swensen
Andrine R. Swensen
HBHoward G. Birnbaum
Howard G. Birnbaum
KSKristina Secnik
Kristina Secnik
MMMaryna Marynchenko
Maryna Marynchenko
PGPaul Greenberg
Paul Greenberg
ACAmi Claxton
Ami Claxton

1 October 2006 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
HBHoward G. Birnbaum
Howard G. Birnbaum
AWAlan G. White
Alan G. White
JRJennifer L. Ba Reynolds
Jennifer L. Ba Reynolds
PGPaul E. Greenberg
Paul E. Greenberg
MZMingliang Zhang
Mingliang Zhang
NKNathaniel P. Katz
Nathaniel P. Katz
Objectives This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States. Methods Costs associated with RxO abuse were grouped into healthcare, criminal justice, and workplace categories. Costs were estimated by either (1) a quantity method that multiplies the number of RxO abusers derived from various national surveys by the estimated per abuser cost, or (2) an apportionment method that starts with overall (ie, prescription and nonprescription) drug abuse costs for a cost component (eg, police protection) and apportions the share of costs based on the prevalence of RxO abuse relative to overall drug abuse. Medical costs in excess of those for otherwise similar nonabusers were based on an analysis of a large administrative claims database for an employed population using multivariate regression methods. Results A lower bound estimate of the costs of RxO abuse in the United States was $8.6 billion in 2001 (or $9.5 billion in 2005 dollars). Of this amount, $2.6 billion were healthcare costs, $1.4 billion were criminal justice costs, and $4.6 billion were workplace costs. Conclusions The costs of RxO abuse represent a substantial economic burden. Rising trends of RxO abuse suggest an escalating economic and public health burden in coming years in the United States, and potentially, elsewhere.